Hims & Hers Health (HIMS) stock declined about 2% yesterday. The fall came after the U.S. Food and Drug Administration (FDA) ...

Hims & Hers stock has dropped over 60% from its peak due to concerns about its GLP-1 business. Read why I think HIMS stock is ...

Citi lowered the firm’s price target on Hims & Hers to $25 from $27 and keeps a Sell rating on the shares. The firm also added a “downside ...

Hims & Hers has shown explosive growth, with potential revenue of $2.5B in FY25, trading at a low 2.4x FY25 sales. Learn more ...

HIMS has experienced similar dramatic drops before. During the 2022 inflation surge, the stock fell 87%, and in 2020, it ...

Hims & Hers' Chief Operating Officer Melissa Baird will transition into an advisory role with the telehealth company in the coming months.